Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial

[1]  L. Leibovici,et al.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. , 2018, The Lancet. Infectious diseases.

[2]  M. Kollef,et al.  Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. , 2017, The Lancet. Infectious diseases.

[3]  J. Timsit,et al.  Update on ventilator-associated pneumonia , 2017, F1000Research.

[4]  J. Vila,et al.  High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial , 2017, The Journal of antimicrobial chemotherapy.

[5]  R. Wunderink,et al.  International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia , 2017, European Respiratory Journal.

[6]  J. Salamzadeh,et al.  Nephrotoxicity of High and Conventional Dosing Regimens of Colistin: A Randomized Clinical Trial , 2017, Iranian journal of pharmaceutical research : IJPR.

[7]  M. Kollef,et al.  A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram‐Negative Ventilator‐Associated Pneumonia: IASIS Trial , 2017, Chest.

[8]  A. Messori,et al.  Non-inferiority of colistin compared with standard care for the treatment of ventilator-associated pneumonia. , 2017, International Journal of Antimicrobial Agents.

[9]  D. Paterson,et al.  Dosing Guidance for Intravenous Colistin in Critically Ill Patients , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Leibovici,et al.  The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  C. Thomson,et al.  Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. , 2016, Annals of the American Thoracic Society.

[12]  Peggy Cruse,et al.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  P. Pezzotti,et al.  Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[14]  M. Antonelli,et al.  Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial , 2015, Trials.

[15]  Fei Wang,et al.  Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis. , 2014, International journal of antimicrobial agents.

[16]  Michael N Neely,et al.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. , 2014, The Lancet. Infectious diseases.

[17]  G. Signoriello,et al.  Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Antonelli,et al.  Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients , 2013, Intensive Care Medicine.

[19]  P. Fey,et al.  What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  K. Ko,et al.  High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. , 2011, American journal of respiratory and critical care medicine.

[21]  G. Iotti,et al.  Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. , 2010, Chest.

[22]  B. Spellberg,et al.  Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  P. Singer,et al.  Effectiveness and safety of colistin: prospective comparative cohort study. , 2010, The Journal of antimicrobial chemotherapy.

[24]  G. Maartens,et al.  Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections , 2009, BMC infectious diseases.

[25]  Garrett E. Schramm,et al.  Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. , 2008, Chest.

[26]  E. Douzinas,et al.  Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. , 2008, The Journal of infection.

[27]  Ian Friedland,et al.  Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study* , 2008, Critical care medicine.

[28]  D. Cook,et al.  Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia* , 2008, Critical care medicine.

[29]  H. Kallel,et al.  Safety and efficacy of colistin compared with imipenem in the treatmentof ventilator-associated pneumonia: a matched case–control study , 2007, Intensive Care Medicine.

[30]  P. J. Z. Teixeira,et al.  Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes. , 2007, The Journal of hospital infection.

[31]  A. Cayuela,et al.  Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings , 2005, Intensive Care Medicine.

[32]  R. Bellomo,et al.  Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group , 2004, Critical care.

[33]  J. Garnacho-Montero,et al.  Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.